1. Home
  2. IFRX vs QSG Comparison

IFRX vs QSG Comparison

Compare IFRX & QSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • QSG
  • Stock Information
  • Founded
  • IFRX 2007
  • QSG 2019
  • Country
  • IFRX Germany
  • QSG China
  • Employees
  • IFRX N/A
  • QSG N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • QSG Other Consumer Services
  • Sector
  • IFRX Health Care
  • QSG Real Estate
  • Exchange
  • IFRX Nasdaq
  • QSG Nasdaq
  • Market Cap
  • IFRX 117.8M
  • QSG 127.3M
  • IPO Year
  • IFRX 2017
  • QSG 2023
  • Fundamental
  • Price
  • IFRX $1.15
  • QSG $2.75
  • Analyst Decision
  • IFRX Strong Buy
  • QSG
  • Analyst Count
  • IFRX 1
  • QSG 0
  • Target Price
  • IFRX $8.00
  • QSG N/A
  • AVG Volume (30 Days)
  • IFRX 623.9K
  • QSG 83.3K
  • Earning Date
  • IFRX 05-07-2025
  • QSG 03-11-2025
  • Dividend Yield
  • IFRX N/A
  • QSG 7.18%
  • EPS Growth
  • IFRX N/A
  • QSG 101.59
  • EPS
  • IFRX N/A
  • QSG 1.04
  • Revenue
  • IFRX $187,930.00
  • QSG $477,141,565.00
  • Revenue This Year
  • IFRX $396.02
  • QSG N/A
  • Revenue Next Year
  • IFRX $155.22
  • QSG N/A
  • P/E Ratio
  • IFRX N/A
  • QSG $2.75
  • Revenue Growth
  • IFRX 177.12
  • QSG N/A
  • 52 Week Low
  • IFRX $1.14
  • QSG $1.47
  • 52 Week High
  • IFRX $2.82
  • QSG $6.22
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 24.46
  • QSG 61.81
  • Support Level
  • IFRX $1.76
  • QSG $2.25
  • Resistance Level
  • IFRX $1.34
  • QSG $3.00
  • Average True Range (ATR)
  • IFRX 0.14
  • QSG 0.19
  • MACD
  • IFRX -0.01
  • QSG 0.03
  • Stochastic Oscillator
  • IFRX 1.39
  • QSG 70.59

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About QSG QuantaSing Group Limited

QuantaSing Group Ltd is a learning service provider in China's adult learning market for personal interest courses. It offers easy-to-understand, affordable, and accessible online courses to adult learners under various brands, including QiNiu, Kelly, and QianChi among others empowering them to pursue personal development. The company offers courses for various domains such as financial literacy, skill upgrading, recreation, and leisure which are offered in live large-class dual-instructor mode, online community-based training camp mode, and in live lecture, one-on-one tutoring mode. Its segments are; Learning service and others which derives key revenue, and Consumer business. Geographically, the company generates all of its revenue from the People's Republic of China.

Share on Social Networks: